N/A
N=24
Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Bottom Line
View on ClinicalTrials.gov: NCT00803517 ↗Enrolled (actual)
24
Serious AEs
—
Results posted
Dec 2008
Primary outcome: Primary: Multifocal Electroretinogram Amplitudes — 28.4; 32.2; 29.7; 36.1 microvolts
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Samsung Medical Center
- Primary completion
- Oct 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Multifocal Electroretinogram Amplitudes |
28.4; 32.2; 29.7; 36.1; 39.9; 37.6 | — |
| SECONDARY Best Corrected Visual Acuity |
0.22; 0.15; 0.07; 0.08; 0.05; 0.04 | — |
Summary
This study is a comparison of multifocal electroretinogram assessment between the laser treatment group and the photodynamic therapy group in chronic central serous chorioretinopathy.
Eligibility Criteria
Inclusion Criteria
- CSC (over 3 months) when subretinal fluid persisted in the subfoveal region demonstrated by clinical examination and OCT
- Ability to maintain steady fixation for mfERG
- Presence of abnormal dilated choroidal vasculature in ICGA
- Symptom duration over 3 months
Exclusion Criteria
- Previous PDT or laser treatment history
- Evidence of CNV in FAG
- Other chorioretinal disorders that can cause macular exudation such as age-related macular degeneration, pathologic myopia, angioid streaks, trauma, inflammatory diseases, retinal vasculopathies, and hereditary dystrophies
Data sourced from ClinicalTrials.gov (NCT00803517). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.